- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
topsav
(< 20)
Submitted: 5/15/2013 12:20:40 PM :
Start Price:
$0.60
NBS Score:
-3.56
upcoming technologies
Recs
neoexmnist
(38.76)
Submitted: 12/18/2012 7:33:14 AM :
Start Price:
$0.65
NBS Score:
-27.24
NeoStem is projected to have their first treatment commercialized in 2017.
Recs
tbotting
(66.22)
Submitted: 12/12/2012 9:25:46 AM :
Start Price:
$0.61
NBS Score:
-20.08
Catalysts in place for the coming year.
Recs
Brilliantdummy
(53.55)
Submitted: 10/29/2012 12:22:31 PM :
Start Price:
$0.66
NBS Score:
-30.35
Allah peanut butter sandwiches;)~
Recs
adzturbot
(57.78)
Submitted: 10/23/2012 10:32:08 PM :
Start Price:
$0.73
NBS Score:
-38.13
rock solid on the current market pullback. Watch this fly once it gets the chance
Recs
Pharmagirl
(< 20)
Submitted: 9/11/2012 11:21:26 PM :
Start Price:
$0.67
NBS Score:
-29.58
Most of the medical profession, maybe not Wall Street, recognizes we've entered a new age in cancer and cardiac care. Thanks to stem cell and genetics research, we're moving from cutting to perhaps curing, or in the very least, offering patients less invasive procedures that may very well help extend their lives.
Recs
ThinkBullish
(< 20)
Submitted: 7/30/2012 11:40:31 AM :
Start Price:
$0.69
NBS Score:
-34.83
Highly undervalued considering the amount of potential it has. I'm not religious but you can't bet against a company backed by the Pope either :)
Recs
GirlsUnder30
(73.86)
Submitted: 7/28/2012 10:46:20 AM :
Start Price:
$0.71
NBS Score:
-39.00
I'm in NY and I know this company. Expect some future stock dilution or debt issues if it stays independent but I expect it will be acquired at some point.
Recs
SamsaricSufferer
(< 20)
Submitted: 7/4/2012 8:14:51 PM :
Start Price:
$0.57
NBS Score:
-21.68
Stem cell expertise.
Recs
valueseeker1
(86.32)
Submitted: 1/20/2012 9:43:34 AM :
Start Price:
$0.74
NBS Score:
-49.39
This is a high risk / high reward extreme speculation, on my part.
This is based on current momentum.
Recs
Imhilion
(66.12)
Submitted: 1/11/2012 2:04:52 PM :
Start Price:
$0.51
NBS Score:
-16.63
Should've put this at five years, long term stem cell research play
Recs
neilepi
(< 20)
Submitted: 12/31/2011 7:49:48 AM :
Start Price:
$0.51
NBS Score:
-19.42
More upside than down. Insider buying.
Recs
M0NEYKLIP
(< 20)
Submitted: 9/14/2011 2:24:56 PM :
Start Price:
$0.68
NBS Score:
-62.75
If you can wait three years and have the stomach to get into the stem cell sector, then this stock is probably going to make you a pretty wealthy investor
Recs
wcinvestments
(< 20)
Submitted: 6/29/2011 10:03:20 AM :
Start Price:
$1.45
NBS Score:
-88.96
The process Neostem uses, and the forward momentum they have will result in this stock being a soon to be winner.
Recs
alfil70
(< 20)
Submitted: 6/24/2011 11:38:09 AM :
Start Price:
$1.37
NBS Score:
-89.09
Stem cells, dealing w/aging. potential to be the next botox, and naturally? Let's wait and see.
Recs
youtwitface
(< 20)
Submitted: 5/12/2011 4:19:57 PM :
Start Price:
$1.66
NBS Score:
+88.90
Company has no real commitment to VSEL technology
Recs
nshamapant
(< 20)
Submitted: 5/8/2011 10:39:34 PM :
Start Price:
$1.77
NBS Score:
-91.26
PCT will boom
Erye still growing
Insider Buying-CEO even receives salary in shares of the company
VSEL supported by Vatican
projected earnings growth of 50% every year for next 3 years. To be profitable by 2013 according to Lifetech Capital
Recs
drt2202
(< 20)
Submitted: 4/26/2011 9:45:55 PM :
Start Price:
$1.96
NBS Score:
-94.32
Neostem is poised for huge growth going forward.
Revenues are expanding sharply. Net losses are shrinking rapidly. And the company sports a solid balance sheet.
The stem cell collection and pharmaceuticals business will help grow the company now and in the future. But the real potential money-maker is the stem cell therapy business. Any positive advances in this area have potential to turn Neostem into the next penny biotech grand slam!
Recs
Woopde
(< 20)
Submitted: 4/15/2011 10:53:37 PM :
Start Price:
$2.00
NBS Score:
-99.14
stem cells are the way to go
Recs
GasparOP
(< 20)
Submitted: 3/14/2011 12:48:13 PM :
Start Price:
$1.58
NBS Score:
-92.80
Neostem is making serious medical progress in an area that is right now cutting-edge and will later be commonplace, fitting my investment philosophy completely, It uses adult stem cells, which is encouraged by Catholic social teaching (the Vatican has a $1 million stake in the company).
Also, it has Chinese exposure, but it isn't totally dependent on them. It's making good acquisitions and being patient. Profitable within two-three years; stock could rise tenfold.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 25 : 1 2 Next »